Research Studies on Real-World Translational Imaging Approaches

 

2021

  • Jakimovski D, Zivadinov R, Bergsland N, Ramasamy DP, Hagemeier J, Genovese AV, Hojnacki D, Weinstock-Guttman B, Dwyer MG (2021) Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. NeuroImage Clinical 29:102554 [Open article]

2020

  • Zivadinov R, Bergsland N, Millman M, Jakimovski D, Ramasamy D, Weinstock-Guttman B, Zarif M, Freedman M, Hunter S, Cohan S, Edwards K, Steingo B, Zabad R, Baker M, Belkin M, Repovic P, Mazhari A, Chase A, Silversteen J, Smith D, Negroski D, Feinberg M, Newman S, Pardo G, Riolo J, Silva D, DeepGRAI Study Group. (2020) Feasibility of thalamic atrophy measurement in clinical routine using artificial intelligence: Results from multi-center, longitudinal study in RRMS patients. 8th Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020:P0577
  • Beadnall H, Weinstock-Guttman B, Wang C, Hagemeier J, Bergsland N, Jakimovski D, Ramanathan M, Ly L, Dwyer M, Schweser F, Hardy T, Benedict R, Barnett M, Zivadinov R (2020) Fingolimod therapy in real world relapsing MS patients: Cognition, quantitative MRI and deep gray matter quantitative susceptibility mapping. 8th Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 September 11-13,:P0874

2019

  • Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C and Weinstock-Guttman B (2019). "Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis." Mult Scler Relat Disord 36: 101388. [Open article]
  • Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D and Zivadinov R (2019). "Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis." J Neuroimaging 29(5): 615-623. [Open article]
  • Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D and Weinstock-Guttman B (2019). "Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study." J Clin Med 8(3). [Open article]
  • Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M and Cohan S (2019). "Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study." J Comp Eff Res 8(5): 305-316. [Open article]
  • Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B and Group M-MS (2019). "Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study." Mult Scler Relat Disord 27: 65-73. [Open article]

2018

  • Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B and Zivadinov R (2018). "Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis." J Neuroimaging 28(5): 490-495. [Open article]
  • Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C and Weinstock-Guttman B (2018). "The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study." CNS Drugs 32(8): 763-770. [Open article]
  • Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B and investigators M-M (2018). "Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS." J Neuroimaging 28(4): 399-405. [Open article]
  • Zivadinov R, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Kolodny S, Silva D, Medin J, Weinstock-Guttman B and group M-Ms (2018). "No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study." Curr Med Res Opin 34(8): 1431-1440. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D and Weinstock-Guttman B (2018). "Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures." J Neurol Sci 388: 175-181. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D and Weinstock-Guttman B (2018). "Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study." J Neurol Sci 387: 152-156. [Open article]
  • Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK and Zivadinov R (2018). "Establishing pathological cut-offs for lateral ventricular volume expansion rates." Neuroimage Clin 18: 494-501. [Open article]
  • Zivadinov R, Hagemeier J, Bergsland N, Tavazzi E, Weinstock-Guttman B (2018) Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. Eur J Neurol 25:584-e536 [Open article]
  • Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R and Group M-MS (2018). "Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study." CNS Drugs 32(1): 75-84. [Open article]
  • Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D and Group M-MS (2018). "Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS." AJNR Am J Neuroradiol 39(2): 289-295. [Open article]

2017

  • Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E and Zivadinov R (2017). "Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis." Neuroimage Clin 15: 769-779. [Open article]
  • Zivadinov R, Khan N, Medin J, Christoffersen P, Price J, Korn JR, Bonzani I, Dwyer MG, Bergsland N, Carl E, Silva D and Weinstock-Guttman B (2017). "An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study." J Neuroimaging 27(3): 339-347. [Open article]

2016

  • Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG and Weinstock-Guttman B (2016). "Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years." Eur J Neurol 23(6): 1101-1109. [Open article]
  • Zivadinov R, Cha C, Buckle G, Aldridge J, Haas G, Reed J, Hughes B (2016) Patient real-world clinical, neurological, tolerability, and safety outcomes for dimethyl fumarate and interferon beta-1a 44 µg subcutaneously three times weekly: A retrospective study using propensity score stratification and matching (PROTRACT). 2nd  Congress of the European Committee for Treatment and Research in Multiple Sclerosis, London, UK September 14-17:P1184